Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Carey, Lisa A., Berry, Donald A., Cirrincione, Constance T., Barry, William T., Pitcher, Brandelyn N., Harris, Lyndsay N., Ollila, David W., Krop, Ian E., Henry, Norah Lynn, Weckstein, Douglas J., Anders, Carey K., Singh, Baljit, Hoadley, Katherine A., Iglesia, Michael, Cheang, Maggie Chon U., Perou, Charles M., Winer, Eric P., Hudis, Clifford A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2016
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4980567/
https://ncbi.nlm.nih.gov/pubmed/26527775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1268
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker